Authors
Latest:
Dr. Figlin on TKI Therapy Options in Renal Cell CarcinomaRobert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology and associate director of academic program development in the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses tyrosine kinase inhibitors that he uses to treat patients with renal cell carcinoma.
Latest:
Dr. Siegel Discusses RT-Related AEs for Patients With Oropharyngeal Squamous Cell CarcinomasRobert Siegel, MD, chair, professor of medicine, director, Division of Hematology/Oncology, George Washington University, discusses the adverse events (AEs) associated with radiation therapy (RT) for patients with oropharyngeal squamous cell carcinomas.
Latest:
Dr. Bosse on the Safety Profile With Radium-223 Plus VEGF in RCCDominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the safety profile demonstrated with the combination of radium-223 and VEGF-targeted therapy for patients with renal cell carcinoma (RCC).
Latest:
Dr. Ai on the FDA Approval of Mogamulizumab in CTCLWei Z. Ai, MD, hematologist, University of California, San Francisco, discusses the FDA approval of mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy.
Latest:
Dr. Flinn on FDA Approval of Tisagenlecleucel in DLBCLIan W. Flinn, MD, PhD, director of Lymphoma Research, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of the chimeric antigen receptor T-cell therapy tisagenlecleucel (Kymriah) for use in adult patients with relapsed/refractory large B-cell lymphoma—including diffuse large B-cell lymphoma.
Latest:
Dr. Gieschen on the Side Effects of Radiation Therapy in NSCLCHolger L. Gieschen, MD, assistant professor, Department of Radiology, the University of Tennessee Health Science Center, radiation oncologist, West Cancer Center, discusses the safety profile of radiation therapy in patients with non–small cell lung cancers (NSCLC).
Latest:
Dr. Nanus Discusses Adjuvant Therapy for RCCDavid M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses adjuvant therapy for patients with renal cell carcinoma.
Latest:
Dr. Goldberg on Sequencing Following Treatment With Osimertinib in NSCLCSarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses sequencing after therapy with osimertinib (Tagrisso) in EGFR-positive non–small cell lung cancer.
Latest:
Dr. Larner on Integrating Radiation Therapy With Immune Checkpoint Blockade in NSCLCJames Larner, MD, professor and chair of Radiation Oncology, University of Virginia Health System, discusses integrating radiation therapy with immune checkpoint blockade in patients with non–small cell lung cancer (NSCLC).
Latest:
Dr. Pacheco on Frontline Therapy for Patients With EGFR-Mutant NSCLCJose M. Pacheco, MD, an assistant professor of medicine/medical oncology at the Colorado University School of Medicine, discusses frontline therapy for patients with EGFR-mutant non–small cell lung cancer (NSCLC).
Latest:
Dr. Van Veldhuizen Discusses Combination Therapy in RCCPeter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses combination therapy for the treatment of patients with renal cell carcinoma.
Latest:
Dr. Agarwal on Second-Line Therapy Selection in Metastatic RCCNeeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses second-line therapy selection in metastatic renal cell carcinoma.
Latest:
More Data Are Needed For EGFR-Targeted Agents in NSCLCEdward B. Garon, MD, discusses the landscape of EGFR-targeted therapy in non–small cell lung cancer.
Latest:
Dr. Patel on Induction in Patients With Mantle Cell LymphomaKrish Patel, MD, medical oncologist, Swedish Cancer Institute, discusses induction therapy in patients with mantle cell lymphoma (MCL).
Latest:
Dr. Mix on Local Consolidative Therapy in Oligometastatic NSCLCMichael D. Mix, MD, assistant professor of radiation oncology at Upstate University Hospital, discusses the use of local consolidative therapy in patients with oligometastatic non–small cell lung cancer (NSCLC).
Latest:
Mario Sznol, MD, on Patient Selection for Combination Therapy in mRCCMario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses patient selection for combination therapy in metastatic renal cell carcinoma.
Latest:
Dr. Gutierrez on Biomarker-Directed Precision Oncology of Pembrolizumab-Based Combos in NSCLCMartin E. Gutierrez, MD, discusses the biomarker-directed precision oncology of pembrolizumab-based combination therapy in the treatment of patients with non–small cell lung cancer.
Latest:
Dr. McCulloch on the Use of R-BAC in MCL After Progression on BTK TherapyRory McCulloch, MD, vice chair, South West Peninsula, HaemSTAR, hematology registrar, University Hospitals, Plymouth, discusses the use of R-BAC (rituximab [Rituxan],bendamustine, and cytarabine) in patients with mantle cell lymphoma (MCL) who had progressed on initial therapy with a BTK inhibitor.
Latest:
Dr. Joseph on Factors Influencing Frontline Therapy Selection in mRCCRichard W. Joseph, MD, internist and oncologist, Mayo Clinic, discusses considerations for frontline therapy selection in metastatic renal cell carcinoma (mRCC).
Latest:
Dr. Choueiri on Subsequent Combo Therapy After PD-1/PD-L1 Blockade in RCCToni Choueiri, MD, discusses what therapy to give patients with renal cell carcinoma after they have received a PD-1/PD-L1 blockade.
Latest:
Dr. Mudad on RELAY Trial for EGFR-Mutant NSCLCRaja Mudad, MD, FACP, discusses the RELAY trial and using doublet therapy to treat EGFR-mutant non–small cell lung cancer.
Latest:
First-Line Necitumumab Improves Survival in Metastatic Squamous NSCLCA phase III trial exploring necitumumab plus chemotherapy as a first-line therapy for patients with metastatic squamous non-small cell lung cancer has demonstrated an improvement in overall survival when compared to chemotherapy alone.
Latest:
Dr. Robert Motzer Reviews the Phase III COMPARZ StudyRobert J. Motzer, MD, from Memorial Sloan-Kettering Cancer Center, discusses the COMPARZ trial that compared pazopanib to sunitinib as a first-line therapy for patients with metastatic renal cell carcinoma.
Latest:
Dr. Vogelzang Discusses First-Line Axitinib in mRCCNicholas J. Vogelzang, MD, from the Comprehensive Cancer Centers of Nevada, discusses the comparison of axitinib to sorafenib as first-line therapy in patients with metastatic renal cell carcinoma.
Latest:
Dr. Bollard on the Treatment of EBV-Positive LymphomaCatherine Bollard, MBChB, MD, Professor of Pediatrics, Medicine, and Pathology & Immunology, Baylor College of Medicine, discusses the treatment of EBV-positive lymphoma with T-cell therapy.
